Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Hindustan Zinc’s exposure to silver is underpriced, calls for re-rating, says Emkay Global
30/09/2025
Trump's peace plan : Perhaps impossible, but never more necessary
30/09/2025
Saudi Arabia is losing its appetite for oil : Here's what it means
30/09/2025
Jaro Institute shares list flat at IPO price of Rs 890 on NSE, BSE
30/09/2025
Safe-haven buying lifts gold to Rs 1,17,351 per 10 g, silver strengthens amid US shutdown fears
30/09/2025
ETMarkets Smart Talk | Valuation reset creates opportunity for long-term investors : Sumit Bhatnagar
30/09/2025
